Clinical
How to identify and manage pre-myopes
In this article:
First published: October 18, 2020
Last updated: November 11, 2024.
Imagine this clinical picture: your patient is six years old and refraction is plano. Mum is -2.00D and Dad is -4.00D. Clearly this is not a normal refractive state for a six year old, and her parental history of myopia is concerning - this is a pre-myope. How can we consistently identify pre-myopes, explain the concern to parents, and how can we best manage them?
What is pre-myopia?
The International Myopia Institute - Defining and Classifying Myopia report1 clearly defines the pre-myope:
Pre-myopia – a refractive state of an eye of ≤ 0.75 D and > 0.50 D in children where a combination of baseline refraction, age, and other quantifiable risk factors provide a sufficient likelihood of the future development of myopia to merit preventative interventions.
This definition is made because while reducing progression of myopia is "a central goal of myopia research... preventing the onset of myopia is an even more valuable target." Identifying pre-myopia involves recognising a situation where a child has a non-myopic refraction, but a cluster of risk factors and/or "an observed pattern of eye growth" which indicates a high risk of progression to myopia."
Identifying the pre-myope
There are four key principles for assessing risk of myopia onset:
- Family history – one myopic parent increases risk by three-fold, while two myopic parents doubles this risk again2
- Visual environment – less than 90 minutes a day spent outdoors increases risk, especially if combined with more than 3 hours a day spent on near work activities (outside of school time)3
- Binocular vision – Children with higher accommodative convergence (AC/A) ratios, typically seen with esophoria, have an increased risk of myopia development within one year of over 20 times.4 Accommodative lag may also be a risk factor but there is conjecture.5 Intermittent exotropia has also been associated with onset of myopia.6
- Current refraction – the most significant risk factor of this lot for future myopia is if a child exhibits 0.50D or less of manifest hyperopia at age 6-7. This risk is independent of family history and visual environment.
In addition to this, the fastest rate of refractive change in myopic children occurs in the year prior to onset,8 so the child who is less hyperopic than age normal should be closely monitored, especially if concurrent risk factors are evident.
The most significant risk factor for future myopia is if a child is +0.50D or less at age 6-7, independent of all other factors. Also watch closely for the child who loses hyperopia quickly between visits, as the fastest refractive shift in myopes occurs in the year just prior to myopia onset.
How quickly should refraction change in emmetropization? The large scale Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study followed almost 5,000 children aged 6 to 14 for over a decade. Measured by cycloplegic autorefraction, emmetropia was defined as refractive error in the horizontal and vertical meridians between +1.00D and -0.25D. In their paper Normal Eye Growth in Emmetropic Schoolchildren,9 Zadnik et al demonstrated that the horizontal meridian changed from a mean of 0.64D at age 6 to 0.28D at age 14, and the vertical meridian from a mean of 0.58D at age 6 to 0.33D at age 14. Putting this into clinical terms:
If your school aged, presumed emmetrope loses 0.50D or more of age-normal hyperopia in a year, you may be looking at a future myope.
Explaining pre-myopia to parents
After you have identified the pre-myope, the next challenge is explaining this to parents. The Myopia Profile Managing Myopia Guidelines Infographic, patient brochure and customizable insert (free to download) help to explain risk using a racing car analogy - each of the risk factors above 'fuels' the myopia car towards both onset and progression of myopia.
Perhaps the message on managing pre-myopia is even easier to communicate than for myopia management, when the child already needs vision correction. The key message to parents which will gain traction is probably the short-term view - a chance to delay or prevent their child's need for full time wear of glasses or contact lenses. A myopic parent especially will find this easy to understand.
Section 1 from The Myopia Profile Managing Myopia Guidelines Clinical Practice Infographic, from the 'Myopia Management in Practice' side which provides a reference guide for eye care professionals on myopia risk factors, prescribing decision trees, follow up schedules and gauging long term myopia management success.
Importance of managing pre-myopia
Managing the pre-myope is arguably more challenging than managing the myope - as the child does not yet require vision correction, this can take optical treatments off the table. There is also minimal research on interventions for pre-myopia, despite the International Myopia Institute stating that preventing myopia is an "even more valuable target"1 for science and practice than reducing progression after onset.
Prevention is a powerful but difficult target to accomplish. Each earlier year of onset is associated with approximately -0.75 to -1.00D increased myopia later in life.10 Therefore, focusing attention on the formative stages of myopia and proactively managing pre-myopia could have much greater positive repercussions compared to myopia control.
Delaying myopia by 1 year has a similar long-term effect as 3 years of myopia control with current treatments.11-14
Pre-myopia interventions
Increased outdoor time
Children whom spend less time outdoors, are far more likely to develop myopia.15 This is especially the case when two hours or less a day of outdoor time is combined with more than 3 hours of near work outside of schooltime.3
The magic amount of outdoor time is a little difficult to pin down, as research studies will variably define outdoor time by the mean reported time (with groups above and below average) or by the intervention (eg the 'recess outside classroom' program by Wu et al, in Taiwan, which amounted to an extra 40 minutes of outdoor time per day). Xiong et al attempted to find a dose-response effect in their 2017 meta-analysis15 and found that less than 13 hours a week (just under 2 hours a day) was associated with the highest odds ratio for incident myopia. On the basis of five studies investigating a dose response, they found that "an increase of 76 min/day, was needed to obtain a 50% reduction in incident myopia, while an increase of 1 hr/day or 7 hr/week will result in a 45% reduction in incident myopia compared with controls."
Research indicates we should aim to increase outdoor time to a total of around two hours per day, average, to have the greatest effect on delaying or preventing myopia onset.
This is a simple, effective and achievable intervention which also may have positive effects on other factors of a child’s life such as reduction in body mass index (BMI), and less sedentary behaviours.16 Don’t forget to encourage sun safety as well.
Low-concentration atropine
In contrast with managing myopia, where practitioners have numerous options to prescribe treatment; a lack of evidence exists for proactive management of pre-myopes.
Four studies have shown a potential role for low-concentration atropine in delaying onset in children at risk of myopia development.17-20 Overall, varying concentrations of atropine from 0.01% to 0.05% reduced the incidence of myopia and resulted in myopic shifts and axial length growth at around half the rate of the untreated children. Although these studies do not indicate the ideal concentration of atropine to use, the outcomes appear to point to stronger concentrations for younger children. Three of these four studies were conducted on Chinese children, so efficacy for other ethnicities is yet to be determined. From what we know about 0.01% atropine for myopia progression (less effective for Asian children21,22, some efficacy for children in North America23 and European children24), the same could be true for pre-myopia treatment.
New data on low-concentration atropine suggests that it may be useful for delaying the onset of myopia in children at risk. Read more in our article Atropine for pre-myopia.
This is an exciting development for parents and practitioners alike, as compliance may be easier to achieve and monitor with atropine compared with outdoor time. Would you prescribe atropine for a pre-myopic child? Ultimately this comes down to collaborative communication with the parents to gain informed consent.
Myopia control spectacles
HAL lenses have been commercially available since 2022 and have established solid efficacy in controlling axial elongation and myopic progression in myopic children.14 In 2024, Zhang et al investigated the use of highly aspherical lenslet (HAL) spectacle lenses to slow axial elongation and myopic refractive shifts in pre-myopic children.25
This was the first study to explore the early intervention and prevention of myopia using an optical treatment. A 1-year randomized controlled trial was performed where 108 Chinese children aged 6 to less than 10 years (mean age 7.0 years) with spherical equivalent refractive error 0.00 to +2.00 D, were randomly assigned either HAL or single vision lens (SVL) spectacles to wear at least 5 days per week and at least 4 hours per day. All lenses were prescribed with 0.00 dioptres. There was a clear relationship between increased wearing time and smaller changes in AL and SERE. Wearing spectacle lenses with HAL for at least 30 hours per week (exceeding the mean wearing time) significantly reduced AL elongation, with 0.11mm growth in one year compared to 0.27mm in SVL wearers.
This data indicates that pre-myopic children can potentially benefit from wearing HAL spectacles, provided longer wearing hours (at least 30 hours/week) are achieved. Read more about this in our article Spectacles with highly aspheric lenslets for pre-myopia.
As this area of myopia research grows, this may potentially become a very low risk intervention option for some children. Whether other myopia control spectacles lens products are able to demonstrate similar effects is yet to be determined. The biggest concern with prescribing spectacles for a perfectly sighted child is the issue of managing compliance and gaining traction with parents.
Repeated low-level red light (RLRL) therapy
RLRL therapy has received growing attention within the myopia management sphere in recent years as numerous clinical trials have reported the effectiveness of this treatment in slowing axial elongation and myopia progression in children.26 Among these, one study emerged which explored the use of RLRL treatment for pre-myopes.
He et al27 in 2023 assessed the efficacy and safety of RLRL therapy in preventing incident myopia among pre-myopic children. A 12-month randomized clinical trial was conducted in China on 278 children aged 6 to 11 years with pre-myopia, defined as spherical equivalent refractive error ranging from +0.50 D to -0.50 D. Half of the cohort received two, 3-minute RLRL therapy (Eyerising) sessions per day, for five days a week, while the other half were controls. They found reduced myopic shifts of 0.17mm in AL and 0.41D for SER after exposure to repeated low-level red light. For those able to continue therapy uninterrupted (n=9), there was a greater reduction in myopia incidence. The RLRL was well-tolerated by the children with no persistent symptoms or structural changes on OCT.
These early findings suggest RLRL may be a safe and effective therapy for myopia prevention in pre-myopic children. Read more in our article Can red light therapy delay myopia onset?.
Despite the convincing efficacy of RLRL therapy in recent studies, further studies need to confirm tolerance and safety over longer periods and with other RLRL devices. In terms of practical constraints, RLRL remains not widely available outside of China and is awaiting regulatory review in markets such as Australia.
Pre-myopia interventions without direct research evidence (but which may make logical sense)
Treating binocular vision disorders
It would make logical sense that if a child presents with a binocular vision disorder linked to myopia onset, that managing the disorder may reduce risk. These specific disorders are:
- Higher accommodative convergence (AC/A) ratios, typically seen with esophoria, have an increased risk of myopia development within one year of over 20 times.4
- Accommodative lag may also be a risk factor but there is conjecture.5
- Intermittent exotropia (IXT) has also been associated with onset of myopia - 50% of children with IXT are myopic by age 10, and 90% by age 20.6
It's important to note, though, that intervening in the above disorders for the purposes of delaying or preventing myopia onset is not evidence based - no study has been published to this effect. It is worth treating these disorders regardless, especially considering that binocular vision disorders can cause educational delays, asthenopia and headaches in children.28
Plano myopia control contact lenses
There is no evidence that treating children classified as pre-myopic with myopia control contact lenses are effective in preventing the onset of myopia. Contact lenses, by nature, require significant parental intervention, cost and increase the risk of eye infection. However in parents whom perhaps have an older child already in contact lenses, potential strong enthusiasm to utilise an effective treatment is understandable. When faced with clear progressors (children who have rapidly changed from hyperopic to plano) with strong risk factors in the circumstances of a family keen for treatment, weighing the risk and benefits of contact lens treatment up with the patient and parent should be done clearly and carefully. For more information on paediatric contact lens wear, see our blog Contact Lens Safety in Kids.
What to do next for the pre-myope
If the conversation has already occurred with parents on the identification and risks of pre-myopia, and outdoor activity and myopia control options discussed - and a child does progress to myopia, this makes subsequent myopia control intervention an easier decision for both practitioner and family.
By identifying pre-myopes as part of your routine clinical paediatric care, you will better integrate myopia control into your practice. Children can progress quickly, especially if you have already identified them as high risk, so ensuring that they are reviewed in at least six-monthly intervals important.
More on managing pre-myopia
Meet the Authors:
About Kate Gifford
Dr Kate Gifford is an internationally renowned clinician-scientist optometrist and peer educator, and a Visiting Research Fellow at Queensland University of Technology, Brisbane, Australia. She holds a PhD in contact lens optics in myopia, four professional fellowships, over 100 peer reviewed and professional publications, and has presented more than 200 conference lectures. Kate is the Chair of the Clinical Management Guidelines Committee of the International Myopia Institute. In 2016 Kate co-founded Myopia Profile with Dr Paul Gifford; the world-leading educational platform on childhood myopia management. After 13 years of clinical practice ownership, Kate now works full time on Myopia Profile.
About Cassandra Haines
Cassandra Haines is a clinical optometrist, researcher and writer with a background in policy and advocacy from Adelaide, Australia. She has a keen interest in children's vision and myopia control.
About Brian Peng
Brian is a clinical optometrist based in Sydney, Australia. He graduated with a Master of Clinical Optometry from the University of New South Wales in 2020.
Read Brian's work on our My Kids Vision website, our public awareness platform. Brian also works on development of various new resources across MyopiaProfile.com.
References
- Flitcroft DI, He M, Jonas JB, Jong M, Naidoo K, Ohno-Matsui K, Rahi J, Resnikoff S, Vitale S, Yannuzzi L. IMI - Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M20-M30.
- Jones LA, Sinnott LT, Mutti DO, Mitchell GL, Moeschberger ML, Zadnik K. Parental history of myopia, sports and outdoor activities, and future myopia. Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3524-32.
- Rose KA, Morgan IG, Ip J, Kifley A, Huynh S, Smith W, Mitchell P. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology. 2008 Aug;115(8):1279-85.
- Mutti DO, Jones LA, Moeschberger ML, Zadnik K. AC/A ratio, age, and refractive error in children. Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2469-78.
- Mutti DO, Mitchell GL, Hayes JR, Jones LA, Moeschberger ML, Cotter SA, Kleinstein RN, Manny RE, Twelker JD, Zadnik K, the CLEERE Study Group. Accommodative Lag before and after the Onset of Myopia. Invest Ophthalmol Vis Sci. 2006;47:837-846.
- Ekdawi NS, Nusz KJ, Diehl NN, Mohney BG. The development of myopia among children with intermittent exotropia. Am J Ophthalmol. 2010;149(3):503-507.
- Zadnik K, Sinnott LT, Cotter SA, Jones-Jordan LA, Kleinstein RN, Manny RE, Twelker JD, Mutti DO, Collaborative Longitudinal Evaluation of E, Refractive Error Study Group. Prediction of Juvenile-Onset Myopia. JAMA Ophthalmol. 2015;133:683-689.
- Mutti DO, Hayes JR, Mitchell GL, Jones LA, Moeschberger ML, Cotter SA, Kleinstein RN, Manny RE, Twelker JD, Zadnik K. Refractive error, axial length, and relative peripheral refractive error before and after the onset of myopia. Invest Ophthalmol Vis Sci. 2007;48:2510-2519.
- Zadnik K, Mutti DO, Mitchell GL, Jones LA, Burr D, Moeschberger ML. Normal eye growth in emmetropic schoolchildren. Optom Vis Sci. 2004 Nov;81(11):819-28.
- Bullimore MA, Brennan NA. Myopia: An ounce of prevention is worth a pound of cure. Ophthalmic Physiol Opt. 2023 Jan;43(1):116-121
- Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019 Aug;96(8):556-567.
- Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020 Mar;104(3):363-368.
- Bullimore MA, Johnson LA. Overnight orthokeratology. Cont Lens Anterior Eye. 2020 Aug;43(4):322-332.
- Bao J, Yang A, Huang Y, Li X, Pan Y, Ding C, Lim EW, Zheng J, Spiegel DP, Drobe B, Lu F, Chen H. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2022 Aug;106(8):1171-1176.
- Xiong S, Sankaridurg P, Naduvilath T, Zang J, Zou H, Zhu J, Lv M, He X, Xu X. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017 Sep;95(6):551-566.
- Centis E, Marzocchi R, Di Luzio R, Moscatiello S, Salardi S, Villanova N, Marchesini G; G. C. Croce School of Health Promotion. A controlled, class-based multicomponent intervention to promote healthy lifestyle and to reduce the burden of childhood obesity. Pediatr Obes. 2012 Dec;7(6):436-45.
- Fang PC, Chung MY, Yu HJ, Wu PC. Prevention of myopia onset with 0.025% atropine in premyopic children. J Ocul Pharmacol Ther. 2010 Aug;26(4):341-5.
- Jethani J. Efficacy of low-concentration atropine (0.01%) eye drops for prevention of axial myopic progression in premyopes. Indian J Ophthalmol. 2022 Jan;70(1):238-240.
- Wang W, Zhang F, Yu S, Ma N, Huang C, Wang M, Wei L, Zhang J, Fu A. Prevention of myopia shift and myopia onset using 0.01% atropine in premyopic children - a prospective, randomized, double-masked, and crossover trial. Eur J Pediatr. 2023 Jun;182(6):2597-2606.
- Yam JC, Zhang XJ, Zhang Y, Yip BHK, Tang F, Wong ES, Bui CHT, Kam KW, Ng MPH, Ko ST, Yip WWK, Young AL, Tham CC, Chen LJ, Pang CP. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. JAMA. 2023 Feb 14;329(6):472-481.
- Yam JC, Zhang XJ, Zhang Y, Wang YM, Tang SM, Li FF, Kam KW, Ko ST, Yip BHK, Young AL, Tham CC, Chen LJ, Pang CP. Three-Year Clinical Trial of Low-Concentration Atropine for Myopia Progression Study: Continued Versus Washout: Phase 3 Report. Ophthalmology. 2021 Oct 7:S0161-6420(21)00745-4.
- Lee SS, Lingham G, Blaszkowska M, Sanfilippo PG, Koay A, Franchina M, Chia A, Loughman J, Flitcroft DI, Hammond CJ, Azuara-Blanco A, Crewe JM, Clark A, Mackey DA. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: A randomised clinical trial. Clin Exp Ophthalmol. 2022 Dec;50(9):1001-1012.
- Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, Lang E, Hemmati HD, Chandler SP; CHAMP Trial Group Investigators. Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial. JAMA Ophthalmol. 2023 Oct 1;141(10):990-999.
- Loughman J, Kobia-Acquah E, Lingham G, Butler J, Loskutova E, Mackey DA, Lee SSY, Flitcroft DI. Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol. 2024 May;102(3):e245-e256.
- Zhang Z, Zeng L, Gu D, Wang B, Kang P, Watt K, Zhou J, Zhou X, Chen Z, Yang D, Chen C, Wang X, Zhou X, Chen Z. Spectacle Lenses With Highly Aspherical Lenslets for Slowing Axial Elongation and Refractive Change in Low-Hyperopic Chinese Children: A Randomized Controlled Trial. Am J Ophthalmol. 2024 Aug 27;269:60-68.
- Tang J, Liao Y, Yan N, Dereje SB, Wang J, Luo Y, Wang Y, Zhou W, Wang X, Wang W. Efficacy of Repeated Low-Level Red-Light Therapy for Slowing the Progression of Childhood Myopia: A Systematic Review and Meta-analysis. Am J Ophthalmol. 2023 Aug;252:153-163.
- He X, Wang J, Zhu Z, Xiang K, Zhang X, Zhang B, Chen J, Yang J, Du L, Niu C, Leng M, Huang J, Liu K, Zou H, He M, Xu X. Effect of Repeated Low-level Red Light on Myopia Prevention Among Children in China With Premyopia: A Randomized Clinical Trial. JAMA Netw Open. 2023 Apr 3;6(4):e239612.
- American Optometric Association. Care of the Patient with Accommodative and Vergence Dysfunction (St Louis, 2001). Accessed 19 October 2020.
Enormous thanks to our visionary sponsors
Myopia Profile’s growth into a world leading platform has been made possible through the support of our visionary sponsors, who share our mission to improve children’s vision care worldwide. Click on their logos to learn about how these companies are innovating and developing resources with us to support you in managing your patients with myopia.